Since complement pathways contribute to disease progression in dysferlinopathy [20], C3 and C5 serum levels were evaluated in BlAJ at 6 and 12 months vs 12 m BlAJ+ONX. The gene discussed is C3; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.